Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.69 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.64 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.64 |
| ▸ | SRC | P12931 | 1/20 | 0.62 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.62 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.62 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2079655 | 0.91 | MAPK14 (0.69) | MAPK14DDR2MAPK9SRCMAPK13 | |
| SCHEMBL2082430 | 0.91 | MAPK14 (0.82) | MAPK14DDR2MAPK9SRCMAPK13 | |
| SCHEMBL3189809 | 0.88 | MAPK14 (0.68) | MAPK14DDR2MAPK9MAPK13MAPK12 | |
| SCHEMBL2083622 | 0.84 | MAPK14 (0.83) | MAPK14DDR2MAPK9SRCMAPK13 | |
| SCHEMBL3293954 | 0.84 | MAPK14 (0.62) | MAPK14DDR2MAPK9SRCMAPK13 | |
| SCHEMBL2616997 | 0.83 | MAPK14 (0.82) | MAPK14DDR2MAPK9SRCMAPK13 | |
| SCHEMBL21939057 | 0.83 | MAPK14 (0.84) | MAPK14DDR2MAPK13MAPK12MAPK11 | |
| SCHEMBL2085734 | 0.82 | MAPK14 (0.86) | MAPK14DDR2MAPK9SRCMAPK13 | |
| SCHEMBL4303670 | 0.82 | MAPK14 (0.86) | MAPK14DDR2MAPK9SRCMAPK13 | |
| SCHEMBL2081374 | 0.82 | MAPK14 (0.84) | MAPK14DDR2MAPK9SRCMAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| EP-1836173-A4 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-7531566-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090105230-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2009-04-23 | — | — | US | disclosed |
| US-20090075986-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| EP-1773784-A2 | ANTI-INFLAMMATORY MEDICAMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7202257-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
| WO-2006081034-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006014290-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050288286-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105230-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | MAPK14 56/4885DDR2 3555/4885MAPK9 297/4885 |
| US-20090075986-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | MAPK14 56/4885DDR2 3555/4885MAPK9 297/4885 |
| US-20070037808-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | MAPK14 29/4885DDR2 2382/4885MAPK9 42/4885 |
| US-20050288286-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | MAPK14 56/4885DDR2 3555/4885MAPK9 297/4885 |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | ABL2, ABL1, PTK2 | MAPK14 80/4885DDR2 888/4885MAPK9 296/4885 |
| US-20070191336-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | MAPK14 29/4885DDR2 2382/4885MAPK9 42/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | MAPK14 128/4885DDR2 1099/4885MAPK9 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.